Almirall and Absci Corporation have announced a drug discovery partnership to develop and commercialise AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
The partnership combines Absci’s Integrated Drug Creation platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
The partnership represents Almirall’s first de novo AI drug collaboration and it comes only months after Absci announced it could design and validate de novo therapeutic antibodies using its "zero-shot" generative AI.
Under the terms of the partnership, Absci will apply its de novo generative AI technology to create and commercialise therapeutic candidates for two dermatological targets.
In addition to product royalties, Absci is eligible to receive up to approximately $650min upfront fees, R&D, and post-approval milestone payments across the two programs if all milestones are successfully completed.
“Almirall chose Absci because their de novo platform brings truly novel innovation in solving the industry’s most challenging targets facing high unmet medical need,” said Almirall Executive VP of R&D and CSO, Dr Karl Ziegelbauer.
“Our partnership underlines Almirall’s commitment to target innovative approaches to help patients suffering from severe skin diseases to achieve their dream of leading a healthy life.”
“Our partnership with Almirall marks an important leap forward for dermatologic drug development and is poised to transform the lives of millions managing skin conditions,” said Absci founder and CEO, Sean McClain.
“We believe the collaboration will generate tremendous scientific and technical insights for using AI drug creation to treat chronic inflammatory diseases more broadly."
"Working with a global leader and visionary in skin disease on this ambitious project will accelerate our journey in creating better biologics for a broad range of diseases affecting millions daily.”
